All Immuno-oncology articles
-
NewsEngineered Salmonella strain reduces tumour growth in breast cancer models
A genetically attenuated strain of Salmonella Typhimurium carrying both a pro-apoptotic protein and immune-stimulating epitopes has demonstrated significant reductions in tumour growth and metastatic spread in preclinical models of aggressive breast cancer.
-
ArticleHow dormant cancer cells protect pancreatic tumours from CAR T therapy
Researchers have discovered how dormant pancreatic cancer cells manipulate their surroundings to evade CAR T-cell therapy, identifying a potential therapeutic target for overcoming treatment resistance.
-
NewsCellular atlas of DCIS reveals clues to invasive breast cancer progression
A large-scale single-cell atlas of ductal carcinoma in situ has identified novel stromal structures and microenvironmental features that may help distinguish lesions at risk of progressing to invasive breast cancer.
-
NewsSodium-triggered gel reduces toxicity of bacterial cancer therapy
A sodium-responsive gel designed to encapsulate tumour-targeting Salmonella has demonstrated substantially reduced treatment toxicity without compromising anti-tumour activity in preclinical mouse models, potentially reviving interest in bacterial cancer therapies.
-
NewsPsychedelics and cancer: exploring neurological pathways in tumour biology
A new peer-reviewed review explores whether psychedelic compounds could influence cancer biology through neurological and immune mechanisms, whilst identifying psychological wellbeing as the most credible near-term clinical opportunity.
-
NewsCell reprogramming induces immune structures across seven cancer types
Asgard Therapeutics has shown that its in vivo cell reprogramming platform can reliably induce mature immunogenic tertiary lymphoid structures across seven tumour types.
-
ArticleHow asymmetric binding affinity enables reversible IL-12 switches
Stronger binding isn’t always better. Dr Teresa Barata of FairJourney Bio explains how researchers engineered a dual-specificity antibody switch designed to control IL-12 activity in tumours.
-
NewsNew culture system yields billions of rare dendritic cells for preclinical research
A new 23-day bone marrow culture protocol produces over 1.5 billion conventional type 1 dendritic cells from a single mouse, offering researchers a consistent, high-purity supply of a cell type critical to tumour immunology and vaccine development.
-
NewsDUSP4 protein identified as key to preventing CAR T cell exhaustion
A protein called DUSP4 has been found to help CD8+ T cells resist exhaustion in the tumour microenvironment, with researchers demonstrating that boosting its activity enhances the performance of engineered CAR T cells against colorectal cancer.
-
NewsANO6 protein identified as dual therapeutic target in pancreatic cancer
Researchers at Fox Chase Cancer Center have identified anoctamin 6 (ANO6) as a potential therapeutic target in pancreatic cancer, finding that blocking the protein disrupts both nutrient transfer to tumour cells and immune evasion in preclinical models.
-
NewsYAP/TAZ protein hyperactivity linked to immune evasion via PD-L2 upregulation
Researchers have identified a mechanism by which overactive YAP and TAZ proteins may simultaneously increase cancer cell visibility to the immune system and shield tumours from T-cell attack.
-
Newsp53 activation boosts T-cell potency against solid tumours
UCLA researchers have shown that transiently activating the tumour suppressor protein p53 using an investigational MDM2 inhibitor can reduce exhaustion in engineered T cells and significantly improve their ability to kill melanoma cells in vitro.
-
NewsBispecific antibody targets regulatory T cells to enhance tumour immunity
A bispecific antibody targeting CCR8 and CD3 has demonstrated the ability to deplete immunosuppressive regulatory T cells and slow tumour growth across multiple cancer models.
-
ArticleTargeting SRC-3 to reprogramme regulatory T cells in cancer
Could targeting SRC-3 in regulatory T cells help overcome tumour immunosuppression? Researchers explain how this approach could restore anti-tumour immunity and what remains to be proven in patients.
-
NewsDual-therapy approach targets TNBC energy supply in preclinical study
A combination of a CD276-targeting antibody-drug conjugate and mitochondria-disrupting gene therapy has demonstrated anti-tumour activity in preclinical models of metastatic triple-negative breast cancer.
-
NewsWhy aptamer cancer therapies are struggling to reach the clinic
Aptamers can recognise cancer-associated targets and deliver drugs directly to tumour cells. So why have so few reached the clinic? A new review examines the barriers to their development.
-
NewsBacterial microrobot platform achieves 82 percent tumour inhibition in bladder cancer
A hybrid microrobotic platform combining living bacteria, nanoparticles and targeted chemotherapy has achieved 82.4 percent tumour inhibition in preclinical bladder cancer models.
-
NewsVPS34 inhibition boosts GD2 visibility to enhance neuroblastoma immunotherapy
Penn State researchers have shown that inhibiting the protein VPS34 increases GD2 display on neuroblastoma cell surfaces, making tumours more visible to anti-GD2 antibodies and improving outcomes in preclinical combination studies.
-
NewsKRAS inhibition and CTLA-4 blockade could overcome gastric cancer immunotherapy resistance
Researchers have identified oncogenic KRAS as a key driver of immunosuppression in gastric adenocarcinoma.
-
NewsMathematical model reveals self-reinforcing mechanism behind HE-S2 ADC cancer therapy
A mathematical model developed by researchers from Mass General Brigham and the University of Cyprus suggests that the experimental immunomodulatory antibody-drug conjugate HE-S2 may become progressively more effective as it reduces tumour size.


